Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01978483
Other study ID # Inno-6030
Secondary ID
Status Completed
Phase Phase 1
First received October 31, 2013
Last updated July 23, 2014
Start date November 2013
Est. completion date June 2014

Study information

Verified date July 2014
Source Innovaderm Research Inc.
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Ultraviolet (UV) light is part of normal sunlight and has many effects on human skin and health. One of the harmful effects of long-term UV light exposure is that it can cause skin cancer. The mechanism by which UV light causes skin cancer is not entirely understood. One of the ways UV light causes cancer is by modifying DNA molecules in the cells of the skin. Another mechanism involved in cancer formation by UV light is immunosuppression. By this mechanism, UV light inactivates cells of the immune system of the skin. The immune cells are responsible for the detection and destruction of foreign substances and organisms such as bacterias and viruses but they also recognize and destroy cancer cells. UV light is known to prevent cells of the immune system to destroy cancer cells.

In laboratory experiments, a medication called denosumab has been shown to diminish the inhibition of ultraviolet-induced suppression of skin immunity. In other words, this medication could block the effect of UV on cells of the immune system and might allow patients taking this drug to be better protected from skin cancer.

The objective of this study is to test whether denosumab blocks the immunosuppressive effect of UVB light in healthy subjects. This study is divided into two stages. In the first stage, ten subjects (Cohort 1) will be sensitized to diphenylcyclopropenone (DPCP), a topical sensitizer commonly used for the treatment of alopecia areata and cutaneous warts. By reexposing the subjects to DPCP in incremental doses, dose-response levels of cutaneous hypersensitivity reactions in normal skin will be obtained. This will allow comparison of the normal levels of DPCP-induced cutaneous hypersensitivity (CHS) reaction in non UV-exposed skin (Cohort 1) to the CHS obtained from the two UVB-exposed experimental groups of Cohort 2.

In the second stage of the study, 20 subjects (Cohort 2) will be exposed to an immunosuppressive dose of ultraviolet B (UVB) 24 hours prior to DPCP sensitization. This is expected to result in the abolition of CHS upon rechallenge with DPCP. In order to assess whether denosumab can reverse UVB-induced immunosuppression, the subjects will have previously been randomized to receive a single 1mL injection of either 60 mg denosumab (group A; 10 subjects) or 1 mL saline (group B; 10 subjects) two weeks before UVB exposure. CHS reactions elicited by DPCP rechallenge will be compared between the denosumab and saline groups.


Recruitment information / eligibility

Status Completed
Enrollment 31
Est. completion date June 2014
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 1. Men or postmenopausal women 18 years of age or older at time of consent.

- 2. Male subject or his female partner (this criterion does not apply to post-menopausal female) is willing to use effective contraceptive method for at least 30 days before Day 0 and at least 1 month after the last study drug administration. Effective contraceptive methods are:

1. Barrier methods such as condom, sponge or diaphragm combined with spermicide in foam, gel or cream;

2. Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo-Provera, Evra and Nuvaring;

3. Intrauterine device (IUD);

4. Sterilization such as tubal ligation, hysterectomy or vasectomy;

5. Postmenopausal state for at least 1 year for female subject or female partner of male subject;

6. Same-sex partner;

7. Abstinence.

- 3. Capable of giving informed consent and the consent must be obtained prior to any study related procedures.

- 4. Fitzpatrick skin phototypes II or III.

- 5. Subject weighs 100kg or less.

Exclusion Criteria:

- 1. Conditions or medications causing immunosuppression, photosensitization or phototoxicity.

- 2. Past history of skin cancer or subject having precancerous skin lesions (eg. actinic keratosis).

- 3. Subject has atopic dermatitis (cohort 1)

- 4. Subject has received investigational drugs within the 28 days or 5 half-lives, whichever is longer, prior to Day 0 or plans to during the study period.

- 5. Subject has used any topical medication on arms or buttocks within 14 days of Day 0 or plans to during the study.

- 6. At the investigator's discretion subject has current or past history of alcohol or drug abuse that would interfere with the ability of the subject to comply with the study protocol.

- 7. Hypersensitivity/allergy to denosumab.

- 8. Hypersensitivity/allergy to lidocaine.

- 9. Hypersensitivity/allergy to latex.

- 10. Subject is taking anticoagulant medication except for low dose acetylsalicylic acid.

- 11. Past history of hypocalcemia or predisposing factors (eg, history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, excision of small intestine, severe renal impairment or receiving dialysis).

- 12. Known vitamin D deficiency.

- 13. Creatinine clearance less than 30mL/min (Cohort 2 only).

- 14. Corrected calcium concentration inferior to the normal range (Cohort 2 only).

- 15. Past history of osteonecrosis of the jaw (ONJ) or risk factors for ONJ (poor oral hygiene, periodontal and/or pre-existing dental disease, diagnosis of cancer with bone lesions, invasive dental procedures such as dental extractions or implants within 6 months of the screening visit.)

- 16. Past history of keloids or hypertrophic scarring.

- 17. Prior treatment with diphenylcyclopropenone.

- 18. Treatment with denosumab in the past 12 months.

- 19. Significant limitations in the range of motion of arms or shoulders.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science


Intervention

Drug:
Denosumab

Radiation:
UVB exposure

Drug:
Diphenylcyclopropenone

Normal Saline


Locations

Country Name City State
Canada Innovaderm Research Inc. Montreal Quebec

Sponsors (1)

Lead Sponsor Collaborator
Innovaderm Research Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in dermal thickness: denosumab group vs placebo group of Cohort 2 Mean dermal thickness, as measured by 20 MHz ultrasonography, after challenge with incremental doses of DPCP for subjects randomized to denosumab as compared to subjects randomized to placebo. Three weeks after sensitization to DPCP. No
Secondary Clinical score of contact hypersensitivity reactions: denosumab group vs placebo group of Cohort 2 Mean clinical scores of contact hypersensitivity reaction sites elicited by incremental doses of DPCP challenges between the denosumab group and the placebo group. Three weeks after sensitization to DPCP. No
Secondary Diameters of contact hypersensitivity reactions: denosumab group vs placebo group of Cohort 2 Mean diameters (mm) of contact hypersensitivity reaction sites elicited by incremental doses of DPCP challenges between the denosumab group and the placebo group. Three weeks after sensitization to DPCP. No
Secondary Change in dermal thickness: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2) Mean dermal thickness, as measured by 20 MHz ultrasonography, after challenge with incremental doses of DPCP for subjects previously exposed to UVB as compared to subjects non-exposed to UVB. Three weeks after sensitization to DPCP. No
Secondary Clinical score of contact hypersensitivity reactions: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2) Mean clinical scores of contact hypersensitivity reaction sites elicited by incremental doses of DPCP between UV-exposed skin and non-UV exposed skin. Three weeks after sensitization to DPCP. No
Secondary Diameters of contact hypersensitivity reactions: non UV-exposed (Cohort 1) vs UV-exposed (Cohort 2) Mean diameters of contact hypersensitivity reaction sites elicited by incremental doses of DPCP between UV-exposed skin and non-UV exposed skin. Three weeks after sensitization to DPCP. No
Secondary Gene expression levels: denosumab group vs placebo group of Cohort 2 Differences in gene expression levels of RANK, RANKL and proteins that are regulated by the RANK-RANKL interaction in the denosumab versus placebo groups. At baseline, two weeks after treatment injection, and 24 hours after UVB exposure. No
Secondary Histological pattern of expression of RANKL and other proteins of interest: denosumab group vs placebo group of Cohort 2 Differences in the cutaneous histological pattern of expression of RANK, RANKL and proteins and cells that are involved in RANK-RANKL interaction in the denosumab versus placebo groups. At baseline, two weeks after treatment injection, and 24 hours after UVB exposure. No
See also
  Status Clinical Trial Phase
Recruiting NCT05060991 - Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients Phase 4
Completed NCT02833805 - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia Phase 2
Completed NCT01252537 - Immunosuppression in HIV-infected Patients With Tuberculosis in Ethiopia N/A
Completed NCT00621699 - Pharmacokinetic Drug Interaction Between Ezetimibe and Tacrolimus After Single Dose Administration in Healthy Subjects Phase 1
Completed NCT01678937 - Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents N/A
Completed NCT00788021 - Protective Immunity Project 01 N/A
Active, not recruiting NCT00166842 - Sirolimus Blood Concentrations on Conversion From Oral Solution to Tablets Phase 4
Recruiting NCT05616130 - Pathological Myeloid Activation After Sepsis and Trauma
Completed NCT03117192 - Zinc Supplementation on Cellular Immunity in Thalassemia Major Phase 4
Recruiting NCT01568697 - Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
Not yet recruiting NCT06024226 - Role of MDSCs and Cancer Stem Cells and Their Cross Talks in NSCLC
Not yet recruiting NCT04961229 - Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response Phase 4
Completed NCT03139565 - High Dose vs. Standard Influenza Vaccine in Adult SOT Phase 3
Completed NCT02547753 - Dental Extractions Among Renal Transplant Recipients
Completed NCT01702207 - Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk Phase 4
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00419575 - Renal Transplantation With Immune Monitoring N/A
Completed NCT00783380 - Influenza Vaccination in Immunocompromized Patients Phase 4
Completed NCT04835948 - Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
Recruiting NCT05043870 - Combined Immunosuppression for Pediatric Crohn's Disease Phase 4